TSH: The First-Line Marker for Thyroid Function — A Practitioner Reference
Thyroid stimulating hormone (TSH) is the most sensitive single marker of thyroid function in primary care and a foundational test across endocrinology, women's health, and functional medicine. This spotlight covers the physiology, reference range debates, interpretation pitfalls, and where TSH fits alongside Free T4, Free T3, and thyroid antibodies.
- Published
- Published
- Reading time
- 8 min read
Why TSH is the first-line thyroid marker
TSH sits at the apex of the hypothalamic-pituitary-thyroid (HPT) axis. The anterior pituitary releases TSH in response to thyrotropin-releasing hormone (TRH) from the hypothalamus, and TSH in turn stimulates the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3). The system operates through negative feedback: rising T4 and T3 suppress TSH; falling T4 and T3 elevate it.
This negative feedback architecture is what makes TSH so powerful as a screening test. Because the pituitary is exquisitely sensitive to even small changes in thyroid hormone availability, TSH typically shifts before T4 or T3 abnormalities become measurable. A patient with early hypothyroidism will often show elevated TSH while their Free T4 remains within reference range — the classical biochemical pattern of subclinical hypothyroidism.
The reference range debate
The conventional TSH reference range — typically 0.4 to 4.5 mIU/L depending on the laboratory and assay — has been the subject of substantial debate over the past two decades. Several lines of evidence suggest the upper limit may be too high:
- Population studies excluding subjects with thyroid antibodies show 97.5th percentiles closer to 2.5 mIU/L
- Patients with TSH between 2.5 and 4.5 mIU/L have higher rates of progression to overt hypothyroidism
- Reproductive outcomes (fertility, pregnancy loss) are associated with TSH greater than 2.5 mIU/L
The National Academy of Clinical Biochemistry (NACB) proposed lowering the upper limit to 2.5 mIU/L based on these data. The American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) have not endorsed this change for general adult populations, but ATA recommends a TSH target below 2.5 mIU/L in the first trimester of pregnancy and below 3.0 mIU/L in the second and third trimesters.
Interpretation patterns
The four-quadrant matrix below summarizes the diagnostic patterns practitioners should recognize:
Elevated TSH with low Free T4 — what does it mean?
Overt primary hypothyroidism. The thyroid gland is failing to produce adequate T4, prompting compensatory pituitary TSH elevation. Investigate underlying cause: hashimotos thyroiditis is the most common etiology in iodine-sufficient regions. Test TPO antibodies and Thyroglobulin antibodies to confirm.
Elevated TSH with normal Free T4 — what does it mean?
Subclinical hypothyroidism. The pituitary is detecting reduced thyroid hormone availability before peripheral measurements show abnormality. Management depends on TSH magnitude, symptoms, antibody status, and pregnancy plans. ATA guidelines recommend treatment for TSH greater than 10 mIU/L universally; for TSH 4.5–10 mIU/L, treatment is individualized.
Suppressed TSH with elevated Free T4 — what does it mean?
Overt hyperthyroidism. Common causes include Graves' disease (most common in younger adults), toxic multinodular goitre, toxic adenoma, and subacute thyroiditis. Order TSI (thyroid-stimulating immunoglobulin) and a radioiodine uptake scan to differentiate.
Suppressed TSH with normal Free T4 — what does it mean?
Subclinical hyperthyroidism, or — importantly — possible secondary (pituitary or hypothalamic) hypothyroidism if Free T4 is at the low end of normal. The latter is a critical zebra: a "normal" Free T4 can be inappropriately low if the pituitary is failing. Order Free T3 and consider pituitary imaging if other anterior pituitary hormones are abnormal.
Interfering factors
Several common clinical scenarios can produce TSH results that don't reflect true thyroid function:
-
Biotin supplementation. High-dose biotin (5,000–10,000 mcg daily, common in supplement marketing) interferes with streptavidin-biotin immunoassay platforms used by many laboratories, producing falsely suppressed TSH. Patients should stop biotin for at least 72 hours before testing.
-
Acute illness. Non-thyroidal illness syndrome can suppress TSH transiently, producing patterns mimicking subclinical hyperthyroidism. Defer testing where possible until the patient has recovered.
-
Glucocorticoids. High-dose corticosteroid therapy suppresses TSH centrally. Interpret with awareness of dose and duration.
-
Dopamine and dopamine antagonists. Dopamine infusions suppress TSH; metoclopramide and similar antagonists can elevate it.
-
Time of day. TSH shows a circadian rhythm, peaking in the early hours of the morning. Most ambulatory testing occurs after the natural peak, so this rarely matters clinically — but consistency in collection timing is recommended for serial monitoring.
When TSH alone is not enough
The single-TSH screening approach assumes a healthy HPT axis. Several clinical contexts require pairing TSH with Free T4 (or a full panel) from the outset:
- Suspected secondary hypothyroidism (pituitary or hypothalamic disease)
- Initiation or dose adjustment of thyroid hormone replacement
- Pregnancy or pre-conception assessment
- Symptomatic patients where TSH is within range but clinical suspicion remains high
- Assessment of thyroid hormone resistance syndromes (RTH)
For these scenarios, the Complete Thyroid Panel is the appropriate workup.
Bottom line for practitioners
TSH remains the single most useful screening test for thyroid function. Its interpretation requires context — the patient's symptoms, the laboratory's reference range, concurrent medications, time of day, and the clinical question being asked. When TSH is abnormal or when clinical suspicion persists despite a normal result, expanding to Free T4, Free T3, and antibody testing provides the complete diagnostic picture.
References
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults PMID: 23246686
- Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the ATA for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum PMID: 28056690
- Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling PMID: 16148345
- Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged PMID: 16148346
Tags
Referenced in this article